Formulations of pimavanserin
AssigneeACADIA Pharmaceuticals Inc.
InventorsRavi Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti
Life of this patent
Estimating the term…
Abstract
Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.
Claims20
A pharmaceutically acceptable capsule for orally delivering 34 mg of pimavanserin to a patient, wherein the capsule has a size 3 or 4 capsule shell that encapsulates a blended pimavanserin composition comprising:
- 40 mg granulated pimavanserin tartrate wherein the bulk density of the granulated pimavanserin tartrate is 0.4 to 0.6 g/ml as determined by USP<616>, method 1;
- microcrystalline cellulose having a particle size distribution (D90) of 180 to 340 μm;
- wherein the particle size distribution is measured using laser light scattering with a Malvern Mastersizer 2000 LLS PS system, a Scirocco 2000 dry dispersion unit and a sample size of 10 g.
A pharmaceutically acceptable capsule for orally delivering 34 mg of pimavanserin to a patient, wherein the capsule has a size 3 or 4 capsule shell that contains a blended pimavanserin composition comprising:
- 40 mg granulated pimavanserin tartrate wherein the bulk density of the granulated pimavanserin tartrate is 0.4 to 0.6 g/ml as determined by USP<616>, method 1;
- and
- 57-60% w/w microcrystalline cellulose.
A pharmaceutically acceptable capsule for orally delivering 34 mg of pimavanserin to a patient, wherein the capsule has a size 3 or 4 capsule shell that contains a blended pimavanserin composition comprising:
- 40 mg granulated pimavanserin tartrate wherein the bulk density of the granulated pimavanserin tartrate is 0.4 to 0.6 g/ml as determined by USP<616>, method 1;
- a filler and a lubricant, wherein
- the D90 particle size distribution of the blended pimavanserin composition is 100 to 300 μm as measured using laser scattering particle size analysis.
A pharmaceutically acceptable capsule for orally delivering 34 mg of pimavanserin to a patient, wherein the capsule has a size 3 or 4 capsule shell that contains a blended pimavanserin composition comprising:
- 40 mg granulated pimavanserin tartrate wherein the bulk density of the granulated pimavanserin tartrate of 0.4 g/ml to 0.6 g/ml as determined by USP<616>, method 1;
- a filler and optionally a lubricant.
Dependencies are inferred from the claim text.